Shares of Tatva Chintan Pharma surged 16.39% to Rs 234.10 on Monday after the company released its Q1 FY27 results. The jump reflected a sharp improvement in the firm’s earnings.
The company’s consolidated net profit more than doubled year‑on‑year, rising from Rs 7 crore in the same quarter last year to Rs 16 crore. Revenue from operations also climbed 43% to Rs 167 crore, up from Rs 116.8 crore a year earlier.
Operating performance improved significantly. EBITDA rose 86.6% YoY to Rs 32.1 crore, and the EBITDA margin expanded to 19.2% from 14.7% a year earlier.
The results were announced after the Board of Directors approved the unaudited standalone and consolidated financial statements for the quarter ended June 30, 2026, at a meeting held on July 17.
The board also re‑appointed Managing Director Chintan Nitinkumar Shah and Whole‑time Directors Ajaykumar Mansukhlal Patel and Shekhar Rasiklal Somani for a further three‑year term, subject to shareholders’ approval at the upcoming annual general meeting.
In addition, the board approved a capacity expansion at the company’s new greenfield manufacturing unit in Dahej‑III, Gujarat. The project will install an aggregate reactor capacity of 344 kilolitres at an estimated cost of Rs 200 crore, financed through a mix of internal accruals and debt.